NextCell Pharma AB (NXTCL) — Cash Flow-to-Debt Ratio
NextCell Pharma AB (NXTCL) has a Cash Flow-to-Debt Ratio of -1.04x as of August 2025, meaning its operating cash flow of Skr-10.77 Million could theoretically repay -1% of its total liabilities (Skr10.34 Million) in one year. See NXTCL current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
NextCell Pharma AB Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for NextCell Pharma AB across 11 annual periods. Also explore NXTCL year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for NextCell Pharma AB (2015–2025)
Year-by-year debt coverage analysis for NextCell Pharma AB. For market capitalisation and broader financial context, see NextCell Pharma AB (NXTCL) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.76x | Skr-38.86 Million | Skr10.34 Million | ▼ -36.1% |
| 2024 | -2.76x | Skr-37.78 Million | Skr13.69 Million | ▲ +17.5% |
| 2023 | -3.35x | Skr-43.83 Million | Skr13.10 Million | ▲ +8.4% |
| 2022 | -3.65x | Skr-33.31 Million | Skr9.12 Million | ▲ +20.9% |
| 2021 | -4.62x | Skr-25.58 Million | Skr5.53 Million | ▲ +13.3% |
| 2020 | -5.33x | Skr-18.96 Million | Skr3.56 Million | ▲ +9.5% |
| 2019 | -5.89x | Skr-22.13 Million | Skr3.76 Million | ▼ -50.8% |
| 2018 | -3.91x | Skr-13.55 Million | Skr3.47 Million | ▲ +32.7% |
| 2017 | -5.80x | Skr-14.82 Million | Skr2.55 Million | ▼ -41.0% |
| 2016 | -4.12x | Skr-11.12 Million | Skr2.70 Million | ▼ -37.2% |
| 2015 | -3.00x | Skr-7.76 Million | Skr2.59 Million | — |